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BIOCHEMICAL CHARACTERIZATION OF THE INTERACTION BETWEEN 
CTCF/YB-1 TRANSCRIPTION FACTORS WITH HPV 16 AND 18 E7 
ONCOPROTEIN AND THEIR INVOLVEMENT DURING C-MYC GENE 
REGULATION IN CELL PROLIFERATION PATHWAY 
 
ABSTRACT 
 
Human Papillomaviruses (HPVs) type HPV-16 and HPV-18 are known as high 
risk HPV, which are cause 95% of cervix cancer. The E7 oncoprotein of HPV is able to 
interact and inactivate cellular protein pRB which further allow progression of the cell 
cycle and trigger cancer development. CTCF is a multivalent transcription factor which 
has been found to interact directly with YB-1. Both are reported to bind synergistically 
on c-myc gene promoter and down regulate the gene. Interaction of E7 oncoprotein of 
HPV16 and 18 to CTCF and YB-1 can help to understand the biological role of this 
oncoprotien in c-myc gene regulation. In this study, the interactions between HPV16 and 
18 E7 with CTCF and YB-1 were characterized biochemically using in-vivo and in-vitro 
assays. This study confirms the novel interaction between HPV16 E7 with CTCF at Zn-
domain and HPV18 E7 with YB-1 at CSD domain and both interactions are direct. 
However CTCF and YB-1 do not interact with HPV18 E7 and HPV16 E7, respectively. 
EMSA has shown that interaction of HPV16 E7 protein towards CTCF~YB-1 complex 
have release YB-1 from the complex that binds to CTCF cognate site FpV. Meanwhile 
the interaction of HPV18 E7 does not disrupt the CTCF~YB-1 complex. However the 
introduction of HPV16 E7 to the complex of CTCF~YB-1~HPV18 E7 disassociate YB-1 
from the complex but forms a new complex CTCF~HPV16 E7~HPV18 E7, this was 
confirmed via a pull-down assay. Therefore, we suggest interaction of E7 protein with 
 xxi
CTCF and YB-1 significantly reduces the formation of CTFC~YB-1 complex. Thus, 
enhances the up-regulation of c-myc promoter and promotes tumourogenesis of cervix.  
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PENCIRIAN BIOKIMIA INTERAKSI ANTARA FAKTOR TRANSKRIPSI CTCF/YB-
1 DENGAN ONKOPROTIN HPV 16 DAN 18 E7 DAN KETERLIBATAN KEDUA-
DUANYA SEMASA PENGAWALATURAN GEN C-MYC DALAM LALUAN 
PROLIFERASI SEL 
 
ABSTRAK 
 
 
Human Papillomaviruses (HPVs) jenis HPV-16 dan HPV-18 digolongkan sebagai 
HPV risiko tinggi yang merupakan 95% punca kanser serviks. Protein E7 HPV boleh 
berinteraksi dan menyahaktifkan protein sellular pRb dan menggalakkan peningkatan 
kitar sel sambil mencetuskan perkembangan kanser. CTCF merupakan faktor transkripsi 
‘multivalent’ yang didapati berinteraksi secara langsung dengan YB-1. Kedua-duanya 
berinteraksi satu sama lain pada promoter gen c-myc dan menindas regulasi transkripsi 
gen tersebut. Maklumat interaksi onkoprotein E7 HPV16 dan 18 terhadap CTCF dan YB-
1 bakal membantu untuk lebih memahami peranan biologi onkoprotien tersebut. Kajian 
ini menaksirkan interaksi biokimia antara onkoprotein E7 HPV16 dan 18 dengan CTCF 
dan YB-1 secara in-vitro dan in-vivo. Kajian ini mendapati wujudnya interaksi antara 
HPV16 E7 dengan CTCF pada Zn-domain, dan HPV18 E7 dengan YB-1 pada CSD, serta 
kedua-dua interaksi berlaku secara langsung. Walau bagaimanapun, CTCF tidak 
menunjukan interaksi dengan HPV18 E7 dan YB-1 tiada interaksi dengan HPV16 E7. 
EMSA menunjukkan bahawa interaksi onkoprotein HPV16 E7 terhadap kompleks 
CTCF~YB-1 telah membebaskan YB-1 daripada kompleks yang terikat pada tapak 
‘cognate’ CTCF (FpV). Selain itu, interaksi HPV18 E7 tidak mengganggu kompleks 
CTCF~YB-1. Seterusnya, penambahan HPV16 E7 pada kompleks CTCF~YB-1~HPV 18 
E7 dapat menyingkirkan YB-1 dan membentuk kompleks baru CTCF~HPV16 
E7~HPV18 E7, hal ini dipastikan dengan kaedah ‘pull-down’. Kami mencadangkan 
 xxiii
bahawa interaksi onkoprotein E7 dengan CTCF dan YB-1 dapat mengurangkan 
pembentukan kompleks CTCF~YB-1 dengan jelas. Seterusnya, meningkatkan regulasi 
gen c-myc dan menggalakkan penularan kanser serviks.   
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Chapter 1: Introduction 
1.1 Research Background and Hypothesis 
 
1.1.1 Human Papillomavirus and cervical cancer 
 
Human Papillomaviruses (HPVs) are circular double-stranded DNA approximately 8000 
base pairs that replicates in the nucleus and have icosahedral capsule that form non-
enveloped virions. There are more than 130 subtypes of HPV and about 70 subtypes 
infect human and 35 of the subtypes infect genital tracts (de Villiers, 1994; Stanley, 
2001). HPV is a risk factor of cervical cancer, the second most common cancer in women 
worldwide after breast cancer. HPV infection has been implicated in the aetiology of 
cervical cancer and more than 90% of cervical cancers contain HPV DNA (Bosch et al., 
1995). Low-risk HPVs such as HPV-6 and HPV-11 causes benign genital warts and 
whereas high-risk types such as HPV 16 and 18 are associated with the development of 
high risk  intra-epithelia squamous lesion (HSIL) and cervical cancer (Walboomers, et 
al., 1999). HPV 16 and 18, represent 58% and 12% in prevalence of cervical cancer, 
respectively (Bosch et al., 2002).  
 
The genome of HPV contains three regions. The two encoding regions called the 
early and late regions encodes for six early and two late genetic open reading frames 
(OFR). The third region, which is both non-coding and small (1000 base pairs), is often 
designated as the non-coding region (NCR), long control region (LCR), or upstream 
regulatory region (URR) (Robboy et al., 2000). The early region covers some 69% of the 
genome and encodes a series of proteins E1, E2, E3, E4, E5, E6 and E7. The viral DNA 
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which integrates into the genome of cancer cells is truncated to various degrees. 
However, E6 and E7 open reading frame are consistently retained and expressed as 
mRNA or protein (Takabe, 1987). Protein E6 is known to bind with protein p53 that 
encodes oncogene p53 that suppress the cell growth. This process deactivate the function 
of p53 gene, thus develops cancer cells (Scheffner et al, 1990; Boyer et al., 1996).  
 
Interaction of E7 protein with retinoblastoma protein pRb leads to disassociation 
of pRb-E2F complex, and stimulates the transcription of cellular genes involved in S-
phase entry (Dyson, 1998; Whyte et al., 1988; Chan et al., 2001). The binding affinity of 
high risk E7 to pRb is 10 fold higher than the low risk (zur Hausen, 1996). E7 open 
reading frame is the most abundant viral protein in cells from cervical cancer and E7 is 
sufficient to immortalize human epithelial cell, and therefore considered as potential 
tumour specific antigen that could be a target of immunotherapy for cervical and 
precancerous (Tindle and Frazer, 1995). Besides that, few studies have indicated that an 
enhanced level of c-Myc was observed in cells expressing HPV E7 (Gewin and 
Galloway, 2001; Oh et al., 2001; DeFilippis et al., 2003). Meanwhile, Abba et al., (2004) 
showed c-myc gene copy number increased according to the grade lesion of cervical 
carcinoma and the results indicate that infection with HPV 16 tightly associated with c-
myc gene amplification. On the other hand, Lui et al., (2007) reported that c-Myc 
expression in the cells transfected with E7 protein showed significant increases the level 
of expression. These findings have confirmed that E7 protein is essential for the 
activation of c-myc gene, but the mechanism is yet to be discovered.  
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1.1.2 CTCF transcription factor 
 
CTCF is a transcription factor which was first identified as the protein 
interacting with three repeats of the CCCTC sequence that regularly spaced at 12-13 
base pairs interval in the chicken c-myc promoter (Lobanenkov et al., 1990). Therefore 
it was named CCCTC Binding Factor or CTCF. CTCF protein was later shown to bind to a 
number of different sequence in the human, mouse and avian c-myc promoters (Lobanenkov et 
al., 1990; Klenova et al., 1993; Fillipova et al., 1996). It has been found that the human 
CTCF gene is localized at the chromosome 16q22.1 locus, a region commonly detected 
in breast and prostate cancer and suggested CTCF gene is a tumour suppressor gene 
(Fillipova et al., 1998). CTCF is a multivalent transcriptional factor with 11 zinc-fingers 
which participate in the binding of DNA elements, promoters, silencer and insulator 
(Fillipova et al., 1996). A number of different target genes regulated by CTCF are implicated 
in a variety of regulatory functions, ranging from promoter repression and activation, to the 
criterion of hormone responsive silencers and enhancer-blocking and/or boundary elements 
between Igf2 and H19 genes (Ohlsson et al., 2001). Transcription of the two imprinted genes 
H19 and Igf2 is controlled in part by CTCF binding insulators located between them (Bell and 
Felsenfeld, 2000; Hark et al., 2000).  
 
On the other hand, Loss of Imprinting (LOI) defines loss of normal pattern of 
expression of a specific parental allele. In cancer it can lead to activation of growth 
promoting imprinted genes such as H19 and Igf2. Douc et al., (1996) have reported the 
methylation status of H19 and Igf2 genes in 29 invasive cervical carcinomas in different 
clinical stages. Fourteen (48%) and 13 (45%) tumours were heterozygous for H19 and 
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Igf2, respectively. LOI of H19 and Igf2 was detected in 2 of 12 (17%) and 5 of 10 
(15%) tumours, respectively. Therefore, suggested that H19 and Igf2 genes, via deletion 
and/or abnormal imprinting, could play a crucial role in a large proportion (58%) of 
cervical cancers where they may be associated with disease progression (Douc et al., 
1996). However, until now there have been no study has been reported of CTCF 
interaction with HPV oncogenes correlating with the tumourogenesis of cervical cancer. 
 
1.1.3 YB-1 transcription factor 
 
The Y-box protein (YB-1) is the highly conserved 70 amino acid DNA domain, 
the so-called ‘cold shock domain’ (CSD) was defined initially in bacteria as a 
characteristic feature of this family (Wolffe et al., 1992). The name Y-box protein 
comes from the ability of the CSD to bind to the Y-box sequence [5’- CTGATTGG – 
3’] of DNA, which is an inverted CCAAT box, in the promoter region of many genes 
(Wolffe et al., 1992 and Wolffe, 1994). It can bind to double and single stranded DNA 
in a sequence-specific manner (Wolffe, 1994), but shows preference for duplex DNA 
enriched with pyrimidines and purines on opposite strands (Ozer et al., 1990 and Sakura 
et al., 1988). Diverse functional roles have attributed the Y-box raging from prokaryotic 
cold shock response to eukaryotic transcription factors, chromatin modification 
proteins, DNA repair proteins, RNA packaging proteins and translational repressors 
(Wolffe, 1994).  
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A correlation has been developed between YB-1 expression and the 
development of malignant phenotype in several tumours such as breast cancer (Bargou 
et al., 1997), osteosarcoma (Oda et al., 1999), colorectal carcinoma (Shibao et al., 
1999) and ovarian scrous adenocarcinoma (Kamura et al., 1999). In addition, the 
presence of YB-1 has been detected in HeLa cells (cervical cancer cells) by 
Shamsuddin (2002), and HPV 18 enhancer oligonucleotide was used as the binding 
material to detect the presence of YB-1 (Spitkovsky et al., 1992). Besides that, 
Chernukhin et al., (2000) have revealed the interaction YB-1 with CTCF towards the 
suppression of c-myc gene. However, there were no reports indicating the mechanism of 
c-Myc expression in cervical carcinoma samples correlating with HPV oncogenes. 
 
1.1.4 Synergistic effect of CTCF and YB-1 towards c-myc oncogene 
 
 
CTCF was known to bind to the CCCTC nucleotide sequence of c-myc promoter 
and YB-1 was known bind to CTCF and synergistically represses the c-myc expression 
(Lobanenkov et al., 1990; Chernukhin et al., 2000) (Figure 1.1). This repression was 
able to control the cell cycle progression and allow the cells to mature in natural 
condition before dividing. However, in cervical carcinoma cells which have been 
infected with HPV 16 and 18 the expression of c-myc was known to be high (Abba et 
al., 2004). Furthermore, the presence of E7 oncoprotein was tightly associated with 
increased level of c-myc expression compare to normal cells (Gewin and Galloway, 
2001; Oh et al., 2001; DeFilippis et al., 2003; Lui et al., 2007). Therefore, this research 
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was carried out to study the effect of E7 oncoprotein of HPV 16 and 18 with 
CTCF~YB-1 complex correlating with the expression of c-myc.   
 
 
 
 
 
 
 
 
 
Figure 1.1: The binding of CTCF~YB-1 complex to the promoter of c-myc gene and down-
regulates the expression of c-myc gene (Chernukhin et al., 2000).  
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1.2 Cervical Cancer  
  
Cervical cancer affects the epithelial cell of the cervix. Cervical cancer is the 
second most common cancer of women worldwide after breast cancer (Parkin et al., 
2001). It is estimated that about 470 000 of new cervical cancer cases occur per annum, 
which contributes towards 1.4 million of invasive cancer of cervix. Cervical cancer is the 
leading cause of the death among women in the developing countries with approximately 
233,000 deaths per annum (Ferlay, 2000). Meanwhile, in Malaysia cancer of the cervix is 
ranked as the second major cause of mortality among women after breast cancer. The 
annual incidence rate of cervical cancer in Malaysia is estimated at 19.7 per 100,000 
population and the incidence rate increases after the age of 30 years, when a peak 
incidence rate at the age of 60-69 years (National Cancer Registry, 2003). For the past 20 
years, the Ministry of Health, Malaysia, has recorded an average of 2,200 new cases per 
year (Ministry of Health Annual Reports 1980-2000).  
 
The etiology of cervical cancer explains how normal columnar epithelial cells of 
the cervix changes to carcinoma. Cervical cancer develops in the lining of the cervix on 
the lower part of uterus that elongate to vigina. Normally the exterior of the cervix 
appears smooth, shiny and moist with a thin layer of mucus coating the surface. 
However, in appearance it looks like florid exophytic cauliflower-like growth during 
cancerous stage (Othman, 2003). Cervical cancer is known to progress through multiple 
processes by increasing severe premalignant dysplastic lesion called cervical 
intraepithelial neoplasia (CIN) I, II, III and carcinoma in-situ, thus progresses to invasive 
carcinoma. The low grade CIN and high grade CIN resembles minimal and greater 
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degree of abnormality (Iwasaka et al., 1998). In nature, columnar epithelial cells 
transform to normal squamous epithelial cells (mature metaplastic) by induction of 
estrogen hormone and acidic vaginal condition. During this transformation stage, 
exposure to the carcinogens and human papillomavirus (HPV) infection contributes 
towards CIN. The carcinogens are chemicals, smoking, alcohol, contraceptive, radiation 
and infection of human papillomavirus (HPV) (Coker et al., 1992; Parazzini et al., 1998; 
Franco et al., 1999). A PCR-based study showed that 99% of invasive cervical cancer 
contains high risk HPV DNA (Munoz, 2000). High risk HPV type 16 and 18 are known 
as high risk HPV because they are strongly associated with cervical carcinoma (zur 
Hausen, 2002).  
 
 
The high risk HPVs exerts their oncogenicity by constitutively expressing two 
major oncoproteins E6 and E7 (Finzer et al., 2002). The interaction of E6 with p53 
causes rapid p53 degradation in a ubiquitin-dependent manner resulting in cell resistance 
to apoptosis and hence chromosomal instability (Scheffner et al., 1993; Rapp and Chen, 
1998; Finzer et al., 2002; zur Hausen, 2002). Meanwhile, E7 binds to pRB and causes the 
release of E2F from E2F/pRB complex, subsequently promotes cell cycle progression 
(Morris et al., 1993; Boyer et al., 1996; Morozov et al., 1997). It has been demonstrated 
that high-risk HPV E6/E7 can efficiently immortalize human primary cells (Shiga et al., 
1997; Thonemann and Schmalz, 2000). Besides that, the high risk HPV E7 proteins is 
able to induce DNA synthesis in quiescent or differentiated cells, thus transforms primary 
baby rat kidney cells (Phelps et al., 1988; Crook et al., 1989; Morozov et al., 1997). 
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Figure 1.2: Pathophysiology of squamous cell carcinoma of the cervix. Hormonally induced 
eversion of the cervix and acidic vaginal environment encourage the 
development of the transformation zone. In physiological conditions, benign 
squamous metaplasia is the eventual outcome. In the presence HPV 16 abd 18, 
the benign metaplasia process is diverted in to a malignant transformation, 
resulting first in increasingly severe grades of cervical intraepithelial neoplasia 
(CIN) and then, progress to invasive squamous cell carcinoma. (Modified from 
Robboy et al., 2000). 
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1.2.1 Cervical cancer and cellular mechanism 
 
 
The development and progression of cervical carcinoma has been shown to 
be dependent on various cellular genetic and epigenetic events, especially 
alterations of the cell cycle machinery at various checkpoints. The precise control of the 
cell cycle in mammalian cells is regulated by the activity of cyclin-dependent 
kinases (CDK1, CDK2, CDK4, CDK6) and their essential activating co-enzymes, the 
cyclins (cyclins A, B, D, E). The kinase activities of these CDKs are regulated by 
the abundance of their partner cyclins, phosphorylation by various kinases, de-
phosphorylation by cell cycle phosphatases, and interaction with CDK-inhibitory 
proteins (CDKIs) [Funk, 1999; Clarke and Chetty, 2001; Milde-Langosch and Riethordf, 
2003]. 
 
The CDK family is an important group of molecules that regulate cell 
proliferation. In addition, two classes of mammalian cyclin-dependent kinase 
inhibitors (CDKIs) have been described: the CIP/KIP family, comprised of p21, p27, 
and p57, and the INK4 family, comprised of p15, p16, p18, and p19 (Sherr and 
Roberts, 1999). The INK4 molecules specifically inhibit cyclin D complexes by 
interaction with the CDK4 and CDK6 components. The KIP family is pro-
miscuous, affecting cyclin E, cyclin A/CDK2, and cyclin B/CDK1 by binding to both 
cyclin and CDK subunit (Clarke and Chetty, 2001). CDKs, cyclins, and CDKIs 
generally function within several defined pathways, including the p16INK4A-Cyclin D1-
CDK4/6-pRb-E2F pathway, the p2lWAF1-p27KIP1-cyclinE-CDK2 pathway, and the 
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p14ARF-MDM2-p53 pathway (Semczuk and Jakowicki, 2004). Each of these 
components plays either a positive or a negative role in cell-cycle control 
mechanisms in cervical carcinogenesis. Besides that, alterations in CDKs, CDKIs, and 
cyclins can lead to uncontrolled proliferation and might contribute to malignant 
transformation of the uterine cervix (Kim and Zhao, 2005). 
 
 
 1.2.1.1 The p16INK4A-cyclin D1-CDK4/6- pRb-E2F pathway 
 
1.2.1.1.1 p16 INK4A 
 
The p16INK4A gene maps to 9p21 and contains three exons, which 
encodes a nuclear phosphoprotein with a molecular weight of 16 kDa. The p16 
protein functions in the negative regulation of the cell cycle through the inhibition 
of cyclin-dependent kinases (CDK) 4 and 6, and interactions with cyclin D1 (Murphy et 
al., 2004). In the absence of p16, CDKs bind to cyclin D1, and the 
Retinoblastoma protein (pRb) is phosphorylated. Phosphorylation of pRb leads to its 
deregulation at the G1/S checkpoint, thus cell proliferation is switched on. In a 
variety of human malignant tumors and cell lines, the p16INK4A gene is inactivated 
by various genetic mechanisms, including point mutations, homozygous 
deletions, and hypermethylation of CpG islands in the p16INK4A promoter 
(Kim and Zhao, 2005). Kim et al., (1998) found a high percentage of p16 exon 
2 mutations in cervical cancer specimens. Meanwhile, Dong et al., (2001) and 
Nuovo et al., (1999) described the hypermethylation of p16 promoter and 
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documented inactivation of the gene as a frequent epigenetic event in cervical 
carcinoma.  
 
The portion of p16-positive samples increases as the tumor progresses from the 
CIN I to the invasive carcinoma stage (Klaes et al., 2001). This indicates over-
expression of the p16 protein is a characteristic of dysplastic and neoplastic 
alterations of the cervical epithelium. Some reports have shown that p16 expression is 
detectable by immunohistochemistry in cervical neoplasia and this expression may 
be a direct result of HPV infection with inactivation of pRb, which is known to 
bind with p16 (Nuovo et al., 1999; Klaes et al., 2001). Squamous cell carcinomas 
(SCCs), high-grade squamous intraepithelial lesions (HSILs), and 
adenocarcinomas (ACs) of the cervix have shown increased p16 immuno-
staining (Marjoniemi, 2004). Klaes et al., (2001) postulated p16 expression was 
restricted to cervical cancer, CIN 2-3, and those cases of CIN 1 associated with 
high-risk HPV types only. 
 
The interaction of p16 with pRb is thought to be central role of p16 in 
controlling cell cycle progression. It has been suggested that HPV infection 
leads to HPV-E7 binding to pRb, which in turn results in increased p16 
expression. Some studies have suggested that p16 expression is induced by E2F 
factor, which disassociates from pRb due to the interaction of pRb with high 
risk HPV E7 oncoprotein (Giarre et al., 2001). The p16 has been used as a 
biomarker for dysplasia in the diagnosis of cervical squamous lesions and has the 
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potential to be used as an additional screening tool (Von Knebel, 2001; Murphy et 
al., 2003; Murphy et al., 2004). The overexpression of p16 is closely associated 
with high-risk HPV infection and high-grade CIN (Guo et al., 2004). A recent 
report showed that in cervical biopsy specimens, the staining pattern of p16 and 
a high percentage of p16-positive cells are closely related to infection with 
high-risk HPV types 16 and 18, and with CIN 2/3 (Saqi et al., 2003; Hu et al., 2005).  
 
1.2.1.1.2 Cyclin D1 
 
 
The cyclin D1 (PRAD-1, CCND-1) gene maps to 11q13 and shows the 
characteristics of a cellular oncogene. Expression of cyclin D1 moderately 
oscillates throughout the cell-cycle, reaching peak levels in G-phase (Semczuk and 
Jakowicki, 2004). Cyclin D1 serves as a key sensor and integrator of extracellular 
signals in early to mid-G1 phase, mediating its function through binding with 
CDKs, histone acetylase, and histone deacetylases to modulate local chromatin 
structure around the genes that are involved in regulation of cell proliferation 
and differentiation. Genetic aberrations in the regulatory circuits that govern 
transit through the G1 phase of the cell cycle occur frequently in human cancer, and 
overexpression of cyclin D1 is one of the most commonly observed alterations (Fu et 
al., 2004).  
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The role of cyclin D1 in cervical carcinogenesis is not clearly understood, 
and controversial results have been described. Cho et al., (1997) found that cyclin 
D1 levels were significantly lower in HPV-positive HSIL, invasive SCC, or 
adenocarcinoma compared to HPV-negative cases and normal cervical epithelium, 
consistent with previous findings (Southern and Herrington, 1998; Bae et al., 2001) 
Contrary to this, the results of Nichols et al., (1996) described elevated cyclin 
D1 mRNA levels in invasive cervical cancer that were not associated with increased 
protein amounts. In addition, there was no significant increase in cyclin D1 protein 
levels were detected in cervical carcinoma, despite overexpression of cyclin D1 
mRNA demonstrated by in-situ hybridization (Cho et al., 1997; Bae et al., 2001).  
 
Few studies showed that the level of cyclin D1 was significantly lower in HPV-
positive LSIL, HSIL, invasive SCC and AC compared to HPV-negative cases and 
normal cervical epithelium (Cho et al., 1997; Southern and Herrington, 1998; Psyrri 
et al., 2004). Cyclin D1 and HPV E7 possess similar binding regions for pRb and pRb-
related pocket proteins, and inactivation of pRb either by the cyclin/CDK 
complexes in G1 phase or by interaction with the high-risk HPV E7 oncoprotein may 
result in a decreased of cyclin D1 expression (Kim and Zhao, 2005).  
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1.2.1.1.3 CDK4 
 
The D-type cyclins (D1, D2, and D3) and their catalytic partners CDK4 and 
CDK6 act in the early G1 phase of the cell cycle (Clarke and Chetty, 2001). 
Mitogen-induced signal transduction pathways promote the activation of cyclin 
D/CDK complexes at different levels such as gene transcription, cyclin D 
translation and stability, assembly of D cyclins with their CDK partners, and 
import of the holoenzymes into the nucleus (where they ultimately phosphorylate 
their substrates). Besides that, cyclin D-dependent kinases (CDK4 and CDK6) can 
phosphorylate pRb family members (pRb, p107, and p130), thus inactivate their 
transcriptional corepressor activities (Kim and Zhao, 2005). 
 
Aberrantly expressed CDK4 could play an important role in cervical 
tumorigenesis. It is postulated that CDK4 oscillates between the INK4 and KIP 
inhibitors by blocking their suppressor activity. In cervical cancer, it was demonstrated 
that the level of INK4 is low compared to CDK4, which would favor the binding of more 
abundant KIP inhibitors to these kinases, and their ability to inhibit of cyclin E is 
disrupted (Kim and Zhao, 2005). The high risk E7 oncoprotein would deregulate pRb 
initially and unleashing E2F-induced cyclin E expression, then the over-expressed CDK4 
binds to KIP molecules, thus allowing cyclin E to become sufficiently active to 
phosphorylate and inactivate pRb and p27KIP1 (Grana and Reddy, 1995; Milde-
Langosch and Riethdorf, 2003; Sheer and Roberts, 2004). 
 
 
 16
Yoshinouchi et al., (2000) have found overexpression of CDK4 in 72.6% of 
cervical cancer specimens and correlates with previous studies of CDK4 expression in 
cervical carcinoma (Skomedal et al., 1999; Cheung et al., 2001). Phosphorylation of 
pRb by CDK4 was found to be non-critical in the carcinogenesis or establishment of 
HPV-positive cervical cancer cell lines, since the HPV oncoproteins E6 and E7 inactivate 
p53 and pRb tumor suppressor functions, respectively, thus resulting in deregulated 
progression of the cell cycle (Yoshinouchi et al., 2000). Interestingly, very recent 
work has indicated that cyclin D/CDK4 complexes phosphorylate Smad3, thus negatively 
regulates the functions of transcriptional complexes that mediate cell growth inhibition 
by TGF family proteins (Matsuura et al., 2004). Importantly, several lines of evidence 
indicate that cyclin D/CDK complexes play a second non-catalytic role in G1 
progression by sequestering proteins of the Cip/Kip family, including p27KIPl and 
p21WAF1/CIP1, two potent inhibitors of CDK2 (Toyoshima and Hunter, 1994; Hall et al., 
1995). 
 
1.2.1.1.4 pRb/E2F 
 
The retinoblastoma tumor suppressor gene (Rb) encodes a nuclear phosphoprotein 
known as pRb, which has been found mutated or deleted in several types of human 
cancer. The pRb and other pRb family members such as p107 and p130 regulate the 
activity of E2F transcription factors (Lukas et al., 1994). Complexes consisting of E2F 
and hypophosphorylated pRb repress the transcription of genes that are required for cell 
cycle progression, and repression is relieved by CDK-mediated phosphorylation of 
pRb (Salcedo et al., 2002). The pRb protein is subjected to regulation by many 
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factors, including E2F and cyclin D1. The hypophosphorylated pRb, complexed with a 
transcription factor, serves as a transcriptional activator of cyclin D1 by binding to its 
promoter (Muller et al., 1994). On the other hand, inactivation of pRb by phosphorylation 
via the cyclin D/CDK complex in late G1 would not only unleash E2F transcription 
factors, but would also decrease cyclin D1 expression (Muller et al., 1994; Clarke and 
Chetty, 2001). High risk HPV E7 oncoprotein was found to interact with hypo- or 
hyper-phosphorylated pRb (Milde-Langosch and Riethdorf, 2003). Therefore, this 
oncoprotein occupies the pRb pocket and displace E2F factors, thus preventing 
pRb/E2F from inducing cyclin D1 transcription and undermining its normal growth-
suppressive function (Salcedo et al., 2002; Fiedler et al., 2004). 
 
 
Both binding and degradation of the Rb proteins by the HPV E7 protein 
are essential for sustained proliferation of HeLa cervical carcinoma cells, and E7 
repression triggers senescence at least in part by activating the Rb pathway in 
both HeLa and HT-3 cells (Lukas et al., 1994). Besides that, pRb immunostaining 
using invasive cervical lesions was frequently lower than in SIL. This low 
level of Rb expression might be resulted from Rb gene mutations or down-regulation 
mechanisms, but may also be related to pRb inactivation resulting from complex 
formation with high-risk HPV E7 oncoproteins (Salcedo et al., 2002). On the other 
hand, mutations in the Rb gene seem to be rare events in cervical cancer (Choo 
and Chong, 1993; Sano et al., 1998). In most studies, Rb gene expression did 
not strictly correlate with the HPV status (Chetty et al., 1997).  
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1.2.1.2 The p21WAF1/CIP1-p27KIP1-cyclin E-CDK2 pathway 
 
1.2.1.2.1 p21WAF1/CIP1 
 
The p2l WAFI/CIPI is a cyclin-dependent kinase inhibitor that associates 
with a class of CDKs and inhibits their kinase activities, leading to cell cycle arrest 
and the dephosphorylation of pRb. A large body of evidence suggests that 
p21WAF1/CIP1 plays an important role in cell fate decisions during growth and 
differentiation (Kim and Zhao, 2005). The p21WAF1/CIP1 protein is a p53-inducible 
protein that inactivates the cyclin/CDK complexes, blocking the cell cycle progression 
in the G1-S transition. However, p21WAF1/CIP1 is expressed in cells undergoing 
either G1 arrest or apoptosis by p53-dependent or -independent mechanisms 
(El-Deiry et al., 1994; Michieli et al., 1994).  
 
The p21WAF1/CIP1 expression usually correlates with favorable prognosis in 
ovarian, gastric, colorectal, and superficial bladder cancers and in esophageal 
squamous cell carcinoma (Kim and Zhao, 2005). However, in cervical cancer, 
the conclusions about p21 expression and its prognostic importance vary 
considerably. Many authors found increased p21 expression in invasive carcinomas 
(Skomedal et al., 1999) and elevated number of p21-expressing cases during the 
progression from normal epithelia through precancerous lesions to invasive 
cervical cancer (Lie et al., 1999; Bae et al., 2001). However, others have detected 
under-expression of p21 in micro-invasive and invasive cervical cancer 
compared to normal cervical epithelium (Kim et al., 1998; Huang et al., 2001). 
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Meanwhile, Van de Putte et al., (2004) did not find any expression of p21 in 
normal squamous cervical epithelium, in agreement with Giannoudis and 
Herrington (2000) and Skomedal et al . ,  (1999)  but in contrast with other 
reports (Kim et al., 1998; Bae et al., 2001). However, the p21 level might be 
increased in a futile attempt to overcome its impaired or bypassed function. In 
squamous cell carcinoma, its function could be impaired through the 
inactivation of p21 by the HPV-16 E7 oncoprotein (Bae et al., 2001). On the 
other hand, (Lu et al., 1998) reported that expression of p2lWAF1/CIP1  was 
correlated with a favorable prognosis in adenocarcinoma of the uterine cervix. 
 
1.2.1.2.2 p27KIP1 
 
The p27KIP1 is a negative regulator of the G1 phase of the cell cycle. The 
p27KIP1 gene is a tumor suppressor gene and is frequently lost in tumor cells. It has 
been implicated in the negative regulation of cell proliferation in response to 
extracellular signals and is induced upon serum deprivation. In normal epithelial 
cells, increased expression of P27KIP1 mediates the arrest of cells in the G1 phase of 
the cell cycle when induced by TGF-β (Sgambato et al., 2000). It was found that 
p27KIP1 associates mainly with the cyclin E/CDK2 and this complex inhibits 
pRb phosphorylation, thus, p27KIP1 blocks the cell from entering S phase (Shiozawa 
et al., 2001). Although p27KIP1 is a putative tumor-suppressor gene, mutation 
or homozygous deletion of this gene is rarely found in human cancer (Huang et al., 
2002). Expression of p27KIP1 protein correlates with human tumor 
progression and Huang et al . ,  (2002) demonstrated that  decrease or 
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absences of p27KIP1 protein expression was associated with more aggressive clinical 
behavior in a variety of human tumors, including breast, lung, colon, gastric, and 
ovarian carcinoma (Huang et al., 2002) 
 
Goff et al.,  (2003) found that p27KIP1 was strongly expressed in both 
the epithelium and stroma of normal cervix, which correlate with other 
investigators. Shiozawa et al., (2001) revealed that the expression of p27KIP1 in 
the normal squamous epithelium of the uterine cervix was observed mainly in the 
intermediate and superficial layers cells, but enlighten weaker expression in the 
parabasal cells, which replicate most actively. This is consistent with a previous study 
conducted by Troncone et al., (1999). The trend of reduced p27KIP1 expression 
in microinvasive and invasive carcinomas further supports the notion that p27KIP1 
plays a tumor suppressor function during neoplastic transformation in cervical 
epithelium. Sgambato et al., (2004) demonstrated that a decrease in p27KIP1 expression 
is associated with the development of cervical cancer and may play an important role 
in the early stage of cervical tumorigenesis (Sgambato et al., 2004). In fact, p27KIP1 
expression has been reduced in pre-invasive lesions of the cervix and became 
progressively more evident during the progression from low- to high-grade SIL and 
from SIL to carcinoma. This result of p27KIP1 expression in cervical carcinomas 
is in agreement with similar findings in several other types of human malig-
nancies (Sgambato, et al., 2000) and with previous reports of cervical cancers 
(Troncone et al., 1999; Shiozawa, 2001).  
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1.2.1.2.3 Cyclin E 
 
 
Cyclin E exists in two isoforms with high homology, designated cyclin El 
and E2. There are no major differences in expression or functions between both have 
been found, and their expression has been assumed to be governed by the same 
molecular circuitry (Geng et al., 2001; Erlandsson et al., 2003). Cyclin E, 
whose catalytic partner is CDK2, is another rate-limiting regulator of the G1 phase of the 
cell cycle (Dirks and Rutka, 1997). Appropriate regulation of this cyclin is essential for 
S-phase transition and numerous processes that determine the accuracy of 
chromosome replication. It can play a role similar to that of cyclin D1, driving the cell 
cycle by phosphorylation of Rb, p107, and p130 and the subsequent release of E2F and 
transcription of key proteins. Cyclin E appears in late G1 after passage through the 
restriction point and disappears again in early S phase (Kim and Zhao, 2005). 
 
Even though gene amplification and post-transcriptional modification are the 
common causes of aberrant cyclin E expression in different malignancies, high-risk-
HPV oncoprotein-associated mechanisms might contribute to the aberrant cyclin 
E expression in cervical lesions. Releasing of E2F factors from pRb by the action of the 
HPV E7 protein could result in the over-expression of cyclin E. This connection, 
however, was not enough to explain the highly expressed cyclin E in cervical 
epithelium. The HPV E7 oncoprotein was demonstrated in complexes with 
cyclin E and cyclin A, thus eliminating phase-dependent variation in activity. Also, 
the HPV E7 was found to interact with p21 and thereby block p21-mediated 
inhibition of cyclin E-associated kinase activity (Zerfass-Thome et al., 1996). 
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In normal cervical squamous epithelium, cyclin E expression was not 
immunohistochemically detectable or was very weak (Cho et al., 1997; Quade et al., 
1988; Kim et al., 2000; Shiozawa et al., 2001; Southern et al., 2001). However, cyclin E 
expression was increased in both low- and high-risk HPV-infected squamous and 
glandular lesions (Cho et al., 1997; Dellas et al., 1998). Cyclin E expression correlated 
strongly with morphologic features of the HPV-infected lesions, and has been 
observed in intermediate, and partly in superficial, cells from LSIL and HSIL, 
implying sequential dysregulation (Southern et al., 2000). Cyclin E over-expression or 
over-activity may be the direct result of the presence of the HPV E6 and E7 proteins in 
invasive disease. The HPV E7 oncoprotein inactivates p27 and leads to decrease 
inhibition of cyclin E, thus promotes its expression (Southern et al., 2001). 
 
1.2.1.2.4 CDK2 
 
The CDK2 functions as an effector through phosphorylation of key substrate such 
as the transcrioption factor p53, the cell cycle regulating phosphatase cdc25A/cdc25C, 
MDM2, BRCA1 and the transcription factor E2F1 (Castedo et al., 2004). E-type cyclins 
(El and E2) govern the activity of the single catalytic subunit of CDK2. Unlike 
various combinations of D-type cyclins that are expressed in different cell types, 
cyclin E-CDK2 complexes are periodic and maximal at the G1 to S phase transition 
(Dulic et al., 1992). Cyclin E-CDK2 also preferentially phosphorylates pRb at 
different sites from the cyclin D-dependent kinases, and these modifications may 
differentially impact on the interactions of pRb with E2Fs, histone deacetylases, 
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and other chromatin-remodeling proteins (Harbour and Dean, 2000). One of the 
most significant consequences of pRb inactivation is activation of cyclin E/CDK2 
subunits, often as a result of increased cyclin E expression (Kim and Zhao, 2005).  
 
The HPV oncoprotein E7 may abrogate p21-mediated sequestration of 
cyclin E and render its catalytic partner CDK2 resistant to p27 (Jones et al., 1997). 
Shiozawa et al., (2001) revealed that no p27 expression was observed in atypical 
epithelial cells of SIL with elevated expression of Ki-67, cyclin E, and CDK2. The 
expression of cyclin-dependent kinases (CDK2 and cdc2) was also increased in 
a considerable number of invasive cervical carcinomas (Kanai et al, 1998; 
Shiozawa et al., 2001). In those cases, p27 expression was also high and retained 
the ability to bind to CDK2, but the p27~cyclin E/CDK2 complex still 
possessed phosphorylating activity (Shiozawa et al., 2001). CDK2 also regulates the 
cell cycle through its interactions with cyclin A2, thus its functions extend 
beyond G1 regulation to govern events in S and G2/M as well. Whereas 
maximal periodic cyclin E-CDK2 activity is detected at Gl/S, low levels of 
cyclin A-CDK2 activity are first detected in late G1 phase. Consistent with crucial roles 
for cyclin E/CDK2 downstream of pRb, many tumor cells are extremely sensitive 
to inactivation of cyclin E/CDK2 whether or not they express pRb. This conclusion 
has been drawn from a multitude of studies demonstrating antiproliferative effects 
of overexpression of p27KIPl, a protein inhibitor of CDK2, or of dominant-negative 
CDK2 subunits (Knockaert et al., 2002; Tetsu and McCormick, 2003). 
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1.2.1.3 The p14 ARF_MDM2-p53 pathway 
 
1.2.1.3.1 P14ARF 
 
The CDKN2A gene on human chromosome 9p21 encodes two distinct proteins, 
p14ARF and p16INK4A, which arise from the same gene by alternative mRNA 
splicing (Kanao et al., 2004). The p14ARF has a mass of 15 kDa and is translated 
from mRNAs bearing a unique first exon, called 1-beta, and located 15 kb 
upstream of the exon 1-alpha of p16INK4A. Both transcripts share common exons 
2 and 3. The p14ARF functions as a cell cycle regulator, stopping cell growth at the 
G1-S border and also at G2-M (Quelle et al., 1995). The p14ARF interaction inhibits 
the MDM2 oncoprotein, thereby blocking formation of the MDM2-p53 complex 
and preventing MDM2-induced p53 degradation (Zhang et al., 1998). Kanao et al., 
(2004) reported that the over-expression of p14ARF and p16INK4A is strongly associated 
with HPV-positive cervical cancers and that reduced expression of p14ARF and p16'NK4A 
is correlated with HPV-negative cervical cancers. These findings may indicate 
that  impaired p14A R F and p16 INK4A mRNA expression contribute to tumor 
development in HPV-negative cervical cancers by failure to support p53 and Rb 
instead of their inactivation by HPV E6 and E7. 
 
In human fibroblasts, it has been shown that p14ARF-induced cell cycle arrest 
is p53-dependent and is abrogated by the co-expression of the HPV E6 protein 
(Stott et al., 1998; Midle-langosch et al., 2001). Therefore, p14ARF up-
regulation was a consequence of inactivation of p53 rather than a sign of cell 
cycle inhibition. Brooks et al., (2002) demonstrated that the expression levels of 
